Comments
Natco Pharma Ltd’s consolidated net profit increased 97 per cent to ₹94 crore in the first quarter ended June 30, 2017, compared to ₹47.5 crore in the corresponding quarter of the previous financial year. The revenue of the Hyderabad-based company grew 30 per cent to ₹449 crore ( ₹345.5 crore). When contacted, M Adinarayana, Vice-President, Natco Pharma, told Business Line that the growth in revenue and profit was driven by positive impact of hepatitis combination products, Tamiflu besides new launches in diabetology and cardiology segments. Natco’s scrip gained 1.22 per cent on the BSE on Monday to end at ₹960.80. Our Bureau
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.